Vitiligo: concise evidence based guidelines on diagnosis and management

Vitiligo is a common disease that causes a great degree of psychological distress. In its classical forms it is easily recognised and diagnosed. This review provides an evidence based outline of the management of vitiligo, particularly with the non-specialist in mind. Treatments for vitiligo are generally unsatisfactory. The initial approach to a patient who is thought to have vitiligo is to make a definite diagnosis, offer psychological support, and suggest supportive treatments such as the use of camouflage cosmetics and sunscreens, or in some cases after discussion the option of no treatment. Active therapies open to the non-specialist, after an explanation of potential side effects, include the topical use of potent or highly potent steroids or calcineurin inhibitors for a defined period of time (usually 2 months), following which an assessment is made to establish whether or not there has been a response. Patients whose condition is difficult to diagnose, unresponsive to straightforward treatments, or is causing psychological distress, are usually referred to a dermatologist. Specialist dermatology units have at their disposal phototherapy, either narrow band ultraviolet B or in some cases photochemotherapy, which is the most effective treatment presently available and can be considered for symmetrical types of vitiligo. Depigmenting treatments and possibly surgical approaches may be appropriate for vitiligo in selected cases. There is no evidence that presently available systemic treatments are helpful and safe in vitiligo. There is a need for further research into the causes of vitiligo, and into discovering better treatments.

[1]  R. Spritz,et al.  Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. , 2010, The Journal of investigative dermatology.

[2]  J. D. Rosso,et al.  A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo , 2010 .

[3]  D. Gawkrodger,et al.  Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. , 2010, The Journal of investigative dermatology.

[4]  R. Wittal,et al.  A randomized, double‐blinded, placebo‐controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo , 2009, The British journal of dermatology.

[5]  M J Watts,et al.  Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.

[6]  J. Hawk,et al.  Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. , 2007, Archives of dermatology.

[7]  J. Naeyaert,et al.  Topical pimecrolimus in the treatment of vitiligo. , 2007, European journal of dermatology : EJD.

[8]  K. Saedi,et al.  The efficacy of combined PUVA and low‐dose azathioprine for early and enhanced repigmentation in vitiligo patients , 2006, The Journal of dermatological treatment.

[9]  D. Ashcroft,et al.  Interventions for vitiligo. , 2006, The Cochrane database of systematic reviews.

[10]  D. Gawkrodger,et al.  Vitiligo presentation in adults , 2005, Clinical and experimental dermatology.

[11]  J. Naeyaert,et al.  Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage , 2005, Dermatology.

[12]  Y. Saral,et al.  Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. , 2005, European journal of dermatology : EJD.

[13]  N. Fallah,et al.  What patients with vitiligo believe about their condition , 2004, International journal of dermatology.

[14]  A. Ehlers,et al.  Measuring adjustment to chronic skin disorders: validation of a self-report measure. , 2003, Psychological assessment.

[15]  B. Moncada,et al.  A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. , 2003, Archives of Dermatology.

[16]  S. Mattoo,et al.  Psychiatric morbidity in vitiligo: prevalence and correlates in India , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  Jonathan A. Smith,et al.  Living with vitiligo: dealing with difference. , 2002, British journal of health psychology.

[18]  H. Hönigsmann,et al.  Oral dexamethasone pulse treatment for vitiligo. , 2001, Journal of the American Academy of Dermatology.

[19]  K. Midthjell,et al.  Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). , 2000, European journal of endocrinology.

[20]  L. Papadopoulos,et al.  Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. , 1999, The British journal of medical psychology.

[21]  W. Westerhof,et al.  Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. , 1999, Archives of dermatology.

[22]  L. Papadopoulos,et al.  Psychological factors in cutaneous disease : an overview of research , 1999 .

[23]  P. Bossuyt,et al.  A systematic review of autologous transplantation methods in vitiligo. , 1998, Archives of dermatology.

[24]  W. Westerhof,et al.  Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. , 1997, Archives of dermatology.

[25]  P. Majumder,et al.  Recent investigations on vitiligo vulgaris. , 1997, Dermatologic clinics.

[26]  J. Wood,et al.  Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. , 1995, Dermatology.

[27]  P. Majumder,et al.  Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. , 1994, American journal of human genetics.

[28]  R. Clayton A double‐blind trial of 0.05% clobetasol proprionate in the treatment of vitiligo , 1977, The British journal of dermatology.

[29]  E. Kandil Treatment of vitiligo with O·1% betamethasone 17‐valerate in isopropyl alcohol—a double‐blind trial , 1974 .

[30]  E. Kandil Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol--a double-blind trial. , 1974, The British journal of dermatology.